A-Alpha Bio Nets $22.4M For Groundbreaking Protein Interaction Predictions
Published by
Benzinga
Benzinga
What do you get when you combine a revolutionary healthcare startup with artificial intelligence (AI) technology? In the case of A-Alpha Bio, the answer is simple: a $22.4 million funding round and a bright future. A-Alpha Bio, born from the University of Washington’s Institute for Protein Design, uses computational tools and yeast experiments to identify therapeutic proteins. It collaborates with drug companies to find ideal agents for testing across various conditions. Don’t Miss: Until 2016 it was illegal for retail investors to invest in high-growth startups. Thanks to changes in federal l…